Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004558 | 0.70 | CYP1A2 (0.42) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL13754864 | 0.70 | CYP1A2 (0.42) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL10711509 | 0.69 | — | — | |
| SCHEMBL8860823 | 0.68 | CYP1A2 (0.43) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL1427719 | 0.65 | CYP1A2 (0.44) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL7678798 | 0.64 | CYP1A2 (0.43) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL21633299 | 0.64 | CYP1A2 (0.43) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL692384 | 0.64 | CYP1A2 (0.43) | KMT2AMEN1CYP1A2TSHRALDH1A1 | |
| SCHEMBL4045529 | 0.63 | TSHR (0.61) | KMT2AMEN1TSHRALDH1A1MAPT | |
| SCHEMBL1186099 | 0.63 | KDM4E (0.68) | KMT2AMEN1CYP1A2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530652-B2 | Pyrrolopyrazoles, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. | 2012-10-18 | — | — | US | disclosed |
| US-8067591-B2 | Pyrrolopyrazole, potent kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-1838718-B1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | ZHANG JUNHU | 2010-09-02 | — | — | US | disclosed |
| EP-1838718-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | Pfizer, Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006072831-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264751-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | KMT2A 2614/4885MEN1 2851/4885CYP1A2 3411/4885 |
| US-20100222342-A1 | PYRROLOPYRAZOLE, POTENT KINASE INHIBITORS | PAK4, PAK5, PAK3 | KMT2A 2962/4885MEN1 3121/4885CYP1A2 3514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.